Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Diluted EPS of $15.32 per share for fiscal year 2025.
VERTEX PHARMACEUTICALS INC / MA Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $15.32 | +836.5% |
| 2024 | -$2.08 | -115.0% |
| 2023 | $13.89 | +8.3% |
| 2022 | $12.82 | +42.3% |
| 2021 | $9.01 | -12.4% |
| 2020 | $10.29 | +128.2% |
| 2019 | $4.51 | -44.3% |
| 2018 | $8.09 | +677.9% |
| 2017 | $1.04 | +326.1% |
| 2016 | -$0.46 | +80.1% |
| 2015 | -$2.31 | +26.4% |
| 2014 | -$3.14 | -58.6% |
| 2013 | -$1.98 | -296.0% |
| 2012 | -$0.50 | -457.1% |
| 2011 | $0.14 | +103.7% |
| 2010 | -$3.77 | -1.6% |
| 2009 | -$3.71 | -13.5% |
| 2008 | -$3.27 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.20 | +4.7% | +5.3% |
| June 30, 2025 | $3.99 | +128.7% | +60.2% |
| March 31, 2025 | $2.49 | -40.9% | -37.9% |
| September 30, 2024 | $4.01 | +1.0% | +128.8% |
| June 30, 2024 | -$13.92 | -495.5% | -430.6% |
| March 31, 2024 | $4.21 | +56.5% | +6.0% |
| September 30, 2023 | $3.97 | +10.6% | +12.8% |
| June 30, 2023 | $3.52 | +12.5% | +30.9% |
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +836.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2008–2025 period, VERTEX PHARMACEUTICALS INC / MA’s diluted eps has grown by 568.5% (from $3.27 per share (loss) to $15.32 per share).
- The most recent figure is from VERTEX PHARMACEUTICALS INC / MA’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: